Literature DB >> 8438591

Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection.

E Björling1, G Scarlatti, A von Gegerfelt, J Albert, G Biberfeld, F Chiodi, E Norrby, E M Fenyö.   

Abstract

Human immunodeficiency virus type 2 (HIV-2) has been reported to be less pathogenic than HIV-1. We have investigated the capacity of sera from nine HIV-2-infected individuals to neutralize their own autologous virus. All nine HIV-2-infected individuals neutralized autologous virus with titers ranging between 20 and 320. In contrast, we have previously reported that most HIV-1-infected individuals lack such antibodies. The difference between HIV-1 and HIV-2 infection was statistically significant (P < 0.0002, Pearson test) and the difference in neutralizing antibody prevalence may explain the faster disease progression in HIV-1-infected individuals than in HIV-2-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438591     DOI: 10.1006/viro.1993.1160

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.

Authors:  Helena Skar; Pedro Borrego; Timothy C Wallstrom; Mattias Mild; José Maria Marcelino; Helena Barroso; Nuno Taveira; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Authors:  Rui Kong; Hui Li; Frederic Bibollet-Ruche; Julie M Decker; Natalie N Zheng; Geoffrey S Gottlieb; Nancy B Kiviat; Papa Salif Sow; Ivelin Georgiev; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination.

Authors:  Samer Sourial; Anette Wärnmark; Charlotta Nilsson; Ewa Björling; Adnane Achour; Robert A Harris
Journal:  Mol Biotechnol       Date:  2005-06       Impact factor: 2.695

6.  Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage.

Authors:  A Mörner; A Björndal; J Albert; V N Kewalramani; D R Littman; R Inoue; R Thorstensson; E M Fenyö; E Björling
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay.

Authors:  P Gomes; N C Taveira; J M Pereira; F Antunes; M O Ferreira; M H Lourenço
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

9.  Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.

Authors:  Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.